Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9NR82

UPID:
KCNQ5_HUMAN

ALTERNATIVE NAMES:
KQT-like 5; Potassium channel subunit alpha KvLQT5; Voltage-gated potassium channel subunit Kv7.5

ALTERNATIVE UPACC:
Q9NR82; A6NKT6; A6PVT6; A8MSQ5; B4DS33; B5MC83; B7ZL37; F5GZV0; Q17RE1; Q5VVP3; Q86W40; Q9NRN0; Q9NYA6

BACKGROUND:
The protein KCNQ5, alternatively named KQT-like 5 or Voltage-gated potassium channel subunit Kv7.5, is integral to forming M-type potassium channels with KCNQ3. These channels are essential for controlling neuronal excitability and exhibit a complex response to various pharmacological agents, including activation by niflumic acid and retigabine, and suppression by muscarinic acetylcholine receptor CHRM1 activation.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in regulating neuronal excitability and its association with Intellectual developmental disorder, autosomal dominant 46, KCNQ5 represents a promising target for drug discovery. Exploring KCNQ5's function and modulation could lead to innovative treatments for neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.